These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 27409827)

  • 1. Targeting αvβ3 and αvβ5 integrins inhibits pulmonary metastasis in an intratibial xenograft osteosarcoma mouse model.
    Gvozdenovic A; Boro A; Meier D; Bode-Lesniewska B; Born W; Muff R; Fuchs B
    Oncotarget; 2016 Aug; 7(34):55141-55154. PubMed ID: 27409827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cilengitide targets pediatric glioma and neuroblastoma cells through cell detachment and anoikis induction.
    Leblond P; Dewitte A; Le Tinier F; Bal-Mahieu C; Baroncini M; Sarrazin T; Lartigau E; Lansiaux A; Meignan S
    Anticancer Drugs; 2013 Sep; 24(8):818-25. PubMed ID: 23728220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cilengitide inhibits attachment and invasion of malignant pleural mesothelioma cells through antagonism of integrins αvβ3 and αvβ5.
    Cheng NC; van Zandwijk N; Reid G
    PLoS One; 2014; 9(3):e90374. PubMed ID: 24595274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency.
    Mikkelsen T; Brodie C; Finniss S; Berens ME; Rennert JL; Nelson K; Lemke N; Brown SL; Hahn D; Neuteboom B; Goodman SL
    Int J Cancer; 2009 Jun; 124(11):2719-27. PubMed ID: 19199360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The inhibitor of integrins Cilengitide: a new active drug in neuro-oncology].
    Leblond P; Meignan S; Le Tinier F; Bethe U; Lansiaux A
    Bull Cancer; 2011 Oct; 98(9):1083-90. PubMed ID: 21914576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small molecule integrin antagonists in cancer therapy.
    Paolillo M; Russo MA; Serra M; Colombo L; Schinelli S
    Mini Rev Med Chem; 2009 Oct; 9(12):1439-46. PubMed ID: 19929817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of alphavbeta3 integrin expression with the metastatic potential and migratory and chemotactic ability of human osteosarcoma cells.
    Duan X; Jia SF; Zhou Z; Langley RR; Bolontrade MF; Kleinerman ES
    Clin Exp Metastasis; 2004; 21(8):747-53. PubMed ID: 16035619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High lung-metastatic variant of human osteosarcoma cells, selected by passage of lung metastasis in nude mice, is associated with increased expression of α(v)β(3) integrin.
    Tome Y; Kimura H; Maehara H; Sugimoto N; Bouvet M; Tsuchiya H; Kanaya F; Hoffman RM
    Anticancer Res; 2013 Sep; 33(9):3623-7. PubMed ID: 24023288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome.
    Weller M; Nabors LB; Gorlia T; Leske H; Rushing E; Bady P; Hicking C; Perry J; Hong YK; Roth P; Wick W; Goodman SL; Hegi ME; Picard M; Moch H; Straub J; Stupp R
    Oncotarget; 2016 Mar; 7(12):15018-32. PubMed ID: 26918452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual αvβ3 and αvβ5 blockade attenuates fibrotic and vascular alterations in a murine model of systemic sclerosis.
    Bagnato GL; Irrera N; Pizzino G; Santoro D; Roberts WN; Bagnato G; Pallio G; Vaccaro M; Squadrito F; Saitta A; Altavilla D; Bitto A
    Clin Sci (Lond); 2018 Jan; 132(2):231-242. PubMed ID: 29237724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of cilengitide in osteoclast maturation and behavior.
    Chillà A; Bianconi D; Geetha N; Dorda A; Poettler M; Unseld M; Sykoutri D; Redlich K; Zielinski CC; Prager GW
    Exp Cell Res; 2015 Sep; 337(1):68-75. PubMed ID: 26209605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disintegrin targeting of an αvβ3 integrin-over-expressing high-metastatic human osteosarcoma with echistatin inhibits cell proliferation, migration, invasion and adhesion in vitro.
    Tome Y; Kimura H; Kiyuna T; Sugimoto N; Tsuchiya H; Kanaya F; Bouvet M; Hoffman RM
    Oncotarget; 2016 Jul; 7(29):46315-46320. PubMed ID: 27331872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cilengitide inhibits metastatic bone colonization in a nude rat model.
    Bretschi M; Merz M; Komljenovic D; Berger MR; Semmler W; Bäuerle T
    Oncol Rep; 2011 Oct; 26(4):843-51. PubMed ID: 21725616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intratibial Injection Causes Direct Pulmonary Seeding of Osteosarcoma Cells and Is Not a Spontaneous Model of Metastasis: A Mouse Osteosarcoma Model.
    Maloney C; Edelman MC; Kallis MP; Soffer SZ; Symons M; Steinberg BM
    Clin Orthop Relat Res; 2018 Jul; 476(7):1514-1522. PubMed ID: 29601385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The disintegrin echistatin in combination with doxorubicin targets high-metastatic human osteosarcoma overexpressing ανβ3 integrin in chick embryo and nude mouse models.
    Tome Y; Kimura H; Sugimoto N; Tsuchiya H; Kanaya F; Bouvet M; Hoffman RM
    Oncotarget; 2016 Dec; 7(52):87031-87036. PubMed ID: 27894082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cilengitide, an αvβ3-integrin inhibitor, enhances the efficacy of anti-programmed cell death-1 therapy in a murine melanoma model.
    Pan X; Yi M; Liu C; Jin Y; Liu B; Hu G; Yuan X
    Bioengineered; 2022 Feb; 13(2):4557-4572. PubMed ID: 35142593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A selective cyclic integrin antagonist blocks the integrin receptors alphavbeta3 and alphavbeta5 and inhibits retinal pigment epithelium cell attachment, migration and invasion.
    Hoffmann S; He S; Jin M; Ehren M; Wiedemann P; Ryan SJ; Hinton DR
    BMC Ophthalmol; 2005 Jun; 5():16. PubMed ID: 15987521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyr61 expression in osteosarcoma indicates poor prognosis and promotes intratibial growth and lung metastasis in mice.
    Sabile AA; Arlt MJ; Muff R; Bode B; Langsam B; Bertz J; Jentzsch T; Puskas GJ; Born W; Fuchs B
    J Bone Miner Res; 2012 Jan; 27(1):58-67. PubMed ID: 21976359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism.
    Cai W; Chen X
    Anticancer Agents Med Chem; 2006 Sep; 6(5):407-28. PubMed ID: 17017851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours.
    Eskens FA; Dumez H; Hoekstra R; Perschl A; Brindley C; Böttcher S; Wynendaele W; Drevs J; Verweij J; van Oosterom AT
    Eur J Cancer; 2003 May; 39(7):917-26. PubMed ID: 12706360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.